Medical management of pancreatic neuroendocrine tumors in patients with MEN 1: case report

J Diabetes Metab Disord. 2022 Jun 29;21(2):2009-2011. doi: 10.1007/s40200-022-01067-3. eCollection 2022 Dec.

Abstract

Objectives: Multiple endocrine neoplasia type 1 (MEN-1) is a rare inherited autosomal dominant disease which manifests itself with at least one clinical scenario before 45 years of age. The value of somatostatin analogue therapy is unknown in the treatment of non-functioning pancreatic tumours and a few studies have been published in this field.

Case presentation: We report a young patient with MEN-1 with multiple gastric and pancreatic neuroendocrine tumors that was treated with the monthly injection of Sandostatin LAR before and After Distal Pancreatectomy and partial gastrectomy.

Conclusions: Now she is well after four years of treatment with Sandostatin LAR.

Keywords: Case management; Multiple endocrine neoplasia; Neuroendocrine tumors; Octreotide.

Publication types

  • Case Reports